Check 35,000+ stocks against 26 valuation models and 37 quality factors

Angelalign Technology Inc (6699) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Angelalign Technology Inc HK$256, price HK$85.40, upside +200.0%, quality 75 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN KYG0405D1051

AT Thin data Oct 1, 2026

Angelalign Technology Inc

6699 · HK

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value HK$256.20 · Strongly undervalued (+200.0%)

✓Quality 75/100

✓Healthy Growth (revenue 5y +26.0 %/yr)

!Thin margins · 9.3% net margin (TTM)

✓Low debt · generates free cash flow

✓1.1% dividend yield · Sustainable

✓Ranks above peers (10/14)

!Moderate moat 50/100

!Evidence only low, so the estimate is less certain

!Weak on dividend: 22 out of 100

26 models, one by oneBear HK$179.34 to bull HK$333.06 Growth analysisrevenue history, year by year Quality 75/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Angelalign Technology Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range HK$43.55 – HK$435.70 · fair‑value band HK$179.34 – HK$333.06 · the HK$85.40 price screens below the HK$256.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.

Follow Angelalign Technology in your weekly email

Every Wednesday you see whether Angelalign Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally. The company's products include Angel Aligner Pro and Angel Aligner Select, a custom made removable clear orthodontic aligners that move the patient's teeth into the proper position over time; Angel Aligner KiD, a early orthodontic solution from prevention to treatment; and Angel Aligner Retainer. It also provides orthodontics and cosmetic dentistry services, and other dental services through its dental clinics. In addition, it sells intraoral scanners, brackets, and other products to hospitals, dental clinics and distributors; and engages in investing activities. Angelalign Technology Inc. was founded in 2003 and is headquartered in Shanghai, China. Angelalign Technology Inc. is a subsidiary of CareCapital Orthotech Limited.

Stock analysis

Angelalign Technology Inc (6699) currently trades at HK$85.40, while our model-based Fair Value estimate is HK$256.20, implying the stock looks roughly 66.7% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$407.00 per share, and 24 of the 26 models we run sit above the HK$85.40 price.

Bear case: the Dividend Discount group reads lowest at HK$75.06, and 2 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$179.34 (bear) to HK$333.06 (bull), the price of HK$85.40 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 75/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Angelalign Technology Inc reported revenue of $2.6B in FY2025 versus $1.3B in FY2021, a compound +19.5%/yr. Reported net income was $199M in FY2025, compounding −8.6%/yr from FY2021.

Key figures

Market cap HK$14.6B (≈ $1.9B) · P/E ratio 45.4 · P/S ratio 3.49 · Dividend yield 1.1% · Net margin 7.7% · Return on equity 8.4% · Return on assets (EBIT) 3.2% · Operating margin 15.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 13% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at 200%, 6699 screens cheaper than that median.

Fair Value models

Bear HK$179.34 Fair Value HK$256.20 Bull HK$333.06

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$372.08 HK$524.48 HK$979.95 78

Growth DCF HK$351.13 HK$555.95 HK$932.77 76

Residual Income HK$118.44 HK$120.05 HK$126.55 76

All 26 models by family

DCF Models

FCF DCF HK$372.08 HK$524.48 HK$979.95 78

Owner Earnings HK$127.32 HK$220.33 HK$392.90 74

5Y Revenue Exit HK$197.31 HK$267.18 HK$409.76 72

5Y EBITDA Exit HK$243.93 HK$361.33 HK$590.05 74

5Y P/E Exit HK$250.75 HK$451.63 HK$715.44 69

10Y Revenue Exit HK$254.59 HK$407.00 HK$473.24 68

10Y EBITDA Exit HK$288.26 HK$498.56 HK$836.61 66

10Y P/E Exit HK$292.81 HK$511.95 HK$849.65 62

Earnings-Based

Graham-Dodd HK$61.89 HK$431.60 HK$605.68 63

Lynch FV HK$180.93 HK$258.47 HK$336.01 61

PEG = 1.0 HK$180.93 HK$258.47 HK$336.01 57

EPV HK$86.59 HK$92.86 HK$98.08 74

Dividend Discount

Gordon GGM HK$45.60 HK$82.17 HK$113.12 68

DDM Multi-Stage HK$45.60 HK$75.06 HK$87.78 67

Multiples

P/E Multiple HK$150.17 HK$200.23 HK$250.28 63

P/S Multiple HK$116.04 HK$154.72 HK$193.40 58

P/B Multiple HK$116.04 HK$154.72 HK$193.40 55

EV/EBIT HK$135.77 HK$167.49 HK$199.21 66

EV/EBITDA HK$180.91 HK$227.67 HK$274.43 67

EV/Revenue HK$108.53 HK$137.64 HK$166.75 54

Asset-Based

NCAV (Graham) HK$79.79 HK$106.92 HK$159.59 54

Growth DCF

Growth DCF HK$351.13 HK$555.95 HK$932.77 76

Rev-Margin DCF HK$202.71 HK$300.32 HK$490.77 71

Economic Profit

Residual Income HK$118.44 HK$120.05 HK$126.55 76

ROIC Compounder HK$86.59 HK$92.86 HK$98.08 72

Growth Earnings

Growth-Adj P/E HK$229.03 HK$327.19 HK$425.35 67

Open the full fair value analysis →

Notify me when 6699 reaches fair value

Put 6699 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 75/100

Of which business quality 74 · Market factors (momentum, volatility) 63

Profitability 38

Margins and returns on capital today

Quality Growth 81

Are margins and returns improving?

Cashflow 85

Earnings quality: real cash, not paper profit

Fin. Strength 91

Balance sheet, leverage, solvency risk

Investment 80

Disciplined investing over empire-building

Low Volatility 45

Calm price path (market factor)

Momentum 74

Price trend over the last 3–12 months (market factor)

52W Momentum 67

Distance to the 52-week high (market factor)

Net Issuance 76

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+32.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+26.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+26.0%

Start year 2020 (pandemic)

Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+26.9%

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.

≈ −2.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year−3.1%

Dividend (yield on the price)1.1%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 6%

⚠ Rate on operating basis: 2025 sits 125% above its own trend.

Growth Forecast

Little optimism in the price

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

less than -40 %

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+16.9%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.2% a year for the forecasts.

Forecast 2026 (sales)+19.1%

Forecast 2027 (sales)+19.8%

Projected 2028 (sales)+17.5%

Projected 2029 (sales)+15.3%

Projected 2030 (sales)+13.1%

Watch 6699, get fair value alerts →

Compare Angelalign Technology Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 201 stocks

Beats the industry median on 6/13 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 75 · Top 25%

Fair Value upside +200.0% · Top 25%

Profitability

Return on equity (TTM) 5.4% · Below median

Return on assets 2.6% · Below median

Net margin (TTM) 7.7% · Above median

Operating margin (TTM) 9.6% · Below median

Growth and dividend

Revenue growth 41.6% · Top 25%

Dividend yield (TTM) 1.1% · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 45.4× · Priciest 25%

P/B 0.53× · Cheapest 25%

P/S (TTM) 4.97× · Priciest 25%

P/FCF 3.5× · Cheapest 25%

EV/EBITDA 22.5× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 23

FUTURE (revenue growth)100 · sector 31

PAST (return on equity)34 · sector 27

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)22 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$405.18	$348.72	−14%
EssilorLuxottica Société anonyme EL	€143.90	€158.29	+10%
Becton, Dickinson and Company BDX	$183.82	$104.73	−43%
Medline Inc MDLN	$34.70	$29.06	−16%
Alcon Inc ALC	$64.47	$40.13	−38%
West Pharmaceutical Services, Inc WST	$375.65	$137.81	−63%
Sartorius Stedim Biotech S.A DIM	€212.40	€54.82	−74%
Straumann Holding STMN	CHF 97.48	CHF 45.50	−53%
Sartorius Aktiengesellschaft SRT	€206.50	€42.05	−80%
Solventum Corporation SOLV	$89.50	$134.36	+50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Angelalign Technology Inc · Fair Value
HK$256.20 +67%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/6699" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Angelalign Technology Inc · Fair Value</span><br><b style="font-size:20px">HK$256.20</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+67%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Angelalign Technology Inc Fair Value". https://www.fairvalue-calculator.com/stock/6699

Frequently asked questions

Is Angelalign Technology Inc (6699) overvalued or undervalued?

As of Oct 1, 2026, our model estimates a fair value of HK$256.20 versus a price of HK$85.40, about +200% upside (undervalued).

What is the fair value of 6699?

Our model-based fair value for Angelalign Technology Inc is HK$256.20 (as of Oct 1, 2026), built from audited fundamentals. The current price: HK$85.40.

What is the quality score of 6699?

Angelalign Technology Inc has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Angelalign Technology Inc (6699)?

Our model-based price target is the fair value of HK$256.20 (as of Oct 1, 2026) from 26 valuation models. Cautious scenario HK$179.34, optimistic scenario HK$333.06. It is a calculation from audited fundamentals, not an analyst target.

What is the Angelalign Technology Inc stock forecast for 2026?

Our models put fair value at HK$256.20, about +200% upside versus a price of HK$85.40 (undervalued). Cautious scenario HK$179.34, optimistic scenario HK$333.06. The calculation is refreshed regularly with new filings.

Does Angelalign Technology Inc pay a dividend?

Angelalign Technology Inc currently shows a dividend yield of about 1.11% relative to its recent price (as of Oct 1, 2026).

What growth is priced into Angelalign Technology Inc (6699)?

For today's price to be fair in a discounted-cash-flow model, Angelalign Technology Inc would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 12.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +26.0 % per year. As of Oct 1, 2026.

What discount rate (WACC) does the fair value of 6699 use?

Our models discount Angelalign Technology Inc at 12.5 %: a base by market capitalisation (small), damped by beta 1.23, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Angelalign Technology Inc that is less than minus 40 % per year a year over ten years, using the same discount rate (12.5 %) and the same formula as our fair value.

How much growth has Angelalign Technology Inc (6699) delivered so far?

Over the past 5 years revenue at Angelalign Technology Inc grew +26.0 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Angelalign Technology Inc (6699) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Angelalign Technology Inc (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Angelalign Technology Inc (6699)?

The free-cash-flow yield on the price is 28.21 %: that much free cash flow Angelalign Technology Inc produces per unit of market value. When it exceeds the discount rate of our models (12.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Angelalign Technology Inc (6699)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Angelalign Technology Inc it is HK$256.20 per share (as of Oct 1, 2026), against a price of HK$85.40. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Angelalign Technology Inc stock overvalued or undervalued in 2026?

As of Oct 1, 2026, 6699 trades below its calculated fair value: price HK$85.40, fair value HK$256.20, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 6699?

No. The price is what the market pays today (HK$85.40); the fair value is what the company's own numbers justify (HK$256.20). For Angelalign Technology Inc the two are HK$170.80 per share apart. That gap is exactly why we show both numbers side by side.

How much is Angelalign Technology Inc worth?

The market values Angelalign Technology Inc at about HK$14.6B (market capitalisation, as of Oct 1, 2026). Per share that is HK$85.40; our models calculate a fair value of HK$256.20 per share.

What do the bullish and bearish scenarios say about 6699?

Our models span a range for Angelalign Technology Inc: cautious scenario HK$179.34, base HK$256.20, optimistic HK$333.06 per share (as of Oct 1, 2026, price HK$85.40). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 6699?

Angelalign Technology Inc trades at a price-to-earnings ratio of 45.4 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$256.20 is built from several models across several years. Other multiples: P/B 0.5, P/S 5.0, EV/EBITDA 22.5.

How solid is the balance sheet of Angelalign Technology Inc (6699)?

Balance-sheet figures for Angelalign Technology Inc (as of Oct 1, 2026): return on equity 5.4%. They feed the Quality Score of 75/100, which measures business quality independently of the share price.

How far is 6699 from its 52-week high?

Angelalign Technology Inc trades at HK$85.40, about 13% below its 52-week high of HK$98.70 and 46% above the low of HK$58.51 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$256.20 is for.

Which stocks are comparable to Angelalign Technology Inc?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Angelalign Technology Inc stock attractive at the current price?

The data as of Oct 1, 2026: price HK$85.40, calculated fair value HK$256.20 (+200%), Quality Score 75/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 6699 calculated?

We run Angelalign Technology Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$256.20, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. Angelalign Technology Inc currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Angelalign Technology Inc (6699)?

The closing price on Sep 30, 2026 was HK$85.40. Our model-based fair value is HK$256.20, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Angelalign Technology Inc right now?

The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (HK$179.34). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$179.34 to HK$333.06) leaves room in how you read the outcome.

Key figures of Angelalign Technology Inc

How large is the market capitalisation of Angelalign Technology Inc (6699)?

The market capitalisation of Angelalign Technology Inc is HK$14.6B (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Angelalign Technology Inc (6699)?

The price-to-sales ratio of Angelalign Technology Inc is 3.49 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the dividend yield of Angelalign Technology Inc (6699)?

The dividend yield of Angelalign Technology Inc is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Angelalign Technology Inc (6699)?

The net margin of Angelalign Technology Inc is 7.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Angelalign Technology Inc (6699)?

The return on equity (ROE) of Angelalign Technology Inc is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Angelalign Technology Inc (6699)?

On an EBIT basis the return on assets of Angelalign Technology Inc is 3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Angelalign Technology Inc (6699)?

The operating margin of Angelalign Technology Inc is 15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Angelalign Technology Inc (6699)?

Revenue at Angelalign Technology Inc is growing +43.0% versus a year earlier (3y avg +26.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Angelalign Technology Inc (6699)?

Earnings per share at Angelalign Technology Inc are growing +84.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Angelalign Technology Inc (6699) hold?

Angelalign Technology Inc holds more cash than debt, $775M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Angelalign Technology Inc in the live analysis

One click puts Angelalign Technology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.